Whether or not such a formulation patent issues and gets included in the Orange Book, I doubt that thrice-weekly Copaxone will attract generic competition unless/until it proves to be a commercial success. I don’t expect NVS/MNTA to file an ANDA for this product.
Market Data 
Markets 
AI
